Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for c-SRC/SRC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human SRC (WT & T338M Mutant) Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Active/Inactive forms. |
View SRC Products |
| Gene Delivery | SRC Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View SRC Products |
| Benchmark Ab | Anti-SRC Recombinant Antibody Recombinant positive control for assay validation (Western Blot, IP, Flow Cytometry). |
View SRC Products |
| Validator | SRC siRNA Set For knockdown verification in functional assays. |
View SRC Products |
| Related Target A | FAK (PTK2) Synergistic focal adhesion signaling partner; co-targeting overcomes SRC-mediated resistance. |
View FAK Products |
| Related Target B | EGFR Crosstalk partner; SRC activation bypasses EGFR inhibition in lung and colorectal cancers. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Src Family Kinase (SFK) selectivity screening | Recombinant SFK panel proteins (Fyn, Yes, Lck, Lyn) strictly verified by mass spectrometry and purity chromatography. |
| Drug resistance profiling (Gatekeeper mutations) | T338M mutant recombinant proteins and matched lentivirus vectors available. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live c-SRC/SRC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for c-SRC/SRC therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to highly selective SRC inhibitors and PROTAC degraders. As first-generation multi-kinase therapies reach clinical matureness, the next wave of R&D is targeting the overcoming of acquired resistance mutations and reducing off-target toxicities associated with broader Src Family Kinase (SFK) inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitors | AstraZeneca, Bristol Myers Squibb | Colorectal Cancer, NSCLC, Breast Cancer | Selectivity Assay (Need SFK homolog panel and mutant proteins) |
| PROTAC Degraders | Arvinas, Academic Spinoffs | Advanced Solid Tumors, Prostate Cancer | Degradation kinetics validation (Need high-purity protein for SPR/FP assays) |
| Combination Therapies | Pfizer, Novartis | EGFR/HER2-resistant malignancies | Synergy validation (Need EGFR, HER2, and FAK pathway proteins) |